| Novel modeling framework to guide design of optimal dosing strategies for β-lactamase inhibitors P Bhagunde, KT Chang, EB Hirsch, KR Ledesma, M Nikolaou, VH Tam Antimicrobial agents and chemotherapy 56 (5), 2237-2240, 2012 | 62 | 2012 |
| Pharmacokinetics, safety, and tolerability of single and multiple doses of relebactam, a β-lactamase inhibitor, in combination with imipenem and cilastatin in healthy participants EG Rhee, ML Rizk, N Calder, M Nefliu, SJ Warrington, MS Schwartz, ... Antimicrobial agents and chemotherapy 62 (9), 10.1128/aac. 00280-18, 2018 | 55 | 2018 |
| Exploring the pharmacokinetic/pharmacodynamic relationship of relebactam (MK-7655) in combination with imipenem in a hollow-fiber infection model J Wu, F Racine, MK Wismer, K Young, DM Carr, JC Xiao, R Katwaru, Q Si, ... Antimicrobial Agents and Chemotherapy 62 (5), 10.1128/aac. 02323-17, 2018 | 51 | 2018 |
| A translational pharmacokinetic/pharmacodynamic model to characterize bacterial kill in the presence of imipenem-relebactam P Bhagunde, Z Zhang, F Racine, D Carr, J Wu, K Young, ML Rizk International Journal of Infectious Diseases 89, 55-61, 2019 | 44 | 2019 |
| Population pharmacokinetic analysis for imipenem–relebactam in healthy volunteers and patients with bacterial infections P Bhagunde, P Patel, M Lala, K Watson, W Copalu, M Xu, P Kulkarni, ... CPT: Pharmacometrics & Systems Pharmacology 8 (10), 748-758, 2019 | 43 | 2019 |
| Discovery of Efficacious Pseudomonas aeruginosa-Targeted Siderophore-Conjugated Monocarbams by Application of a Semi-mechanistic Pharmacokinetic … KE Murphy-Benenato, PR Bhagunde, A Chen, HE Davis, ... Journal of medicinal chemistry 58 (5), 2195-2205, 2015 | 29 | 2015 |
| Mathematical modeling to characterize the inoculum effect P Bhagunde, KT Chang, R Singh, V Singh, KW Garey, M Nikolaou, ... Antimicrobial agents and chemotherapy 54 (11), 4739-4743, 2010 | 22 | 2010 |
| Modelling biphasic killing of fluoroquinolones: guiding optimal dosing regimen design P Bhagunde, R Singh, KR Ledesma, KT Chang, M Nikolaou, VH Tam Journal of antimicrobial chemotherapy 66 (5), 1079-1086, 2011 | 12 | 2011 |
| Pharmacokinetics of elbasvir and grazoprevir in subjects with end-stage renal disease or severe renal impairment L Caro, L Wenning, HP Feng, Z Guo, L Du, P Bhagunde, C Fandozzi, ... European Journal of Clinical Pharmacology 75, 665-675, 2019 | 10 | 2019 |
| Fitusiran, an siRNA therapeutic targeting antithrombin for the treatment of haemophilia: proposed revisions to dose and regimen as a risk mitigation for vascular thrombosis C Negrier, KJ Pasi, MV Ragni, SW Pipe, Y Cue, P Bhagunde 14th Annual Congress of the European Association for Haemophilia and Allied …, 2021 | 8 | 2021 |
| Impact of renal impairment and human organic anion transporter inhibition on pharmacokinetics, safety and tolerability of relebactam combined with imipenem and cilastatin P Bhagunde, F Colon‐Gonzalez, Y Liu, J Wu, SS Xu, G Garrett, P Jumes, ... British Journal of Clinical Pharmacology 86 (5), 944-957, 2020 | 8 | 2020 |
| Modeling heterogeneous bacterial populations exposed to antibiotics: The logistic‐dynamics case PR Bhagunde, M Nikolaou, VH Tam AIChE Journal 61 (8), 2385-2393, 2015 | 7 | 2015 |
| Fitusiran population pharmacokinetic and pharmacodynamic (PopPK/PD) modeling to support revised dose, dosing regimens & dose mitigation scheme P Bhagunde, S Ge, S Iqbal, B Mei, S Andersson, V Kanamaluru ISTH abstract. Res Pract Thromb Haemost 5, 2021 | 5 | 2021 |
| Development of a quantitative systems pharmacology model to explore hemostatic equivalency of antithrombin lowering C Kaddi, M Tao, R Leiser, A Salvador, S Kattula, P Bhagunde, ... Blood 140 (Supplement 1), 5606-5607, 2022 | 2 | 2022 |
| Thorough QTc study of a single supratherapeutic dose of relebactam in healthy participants K Boundy, Y Liu, P Bhagunde, TE O'Reilly, F Colon‐Gonzalez, ... Clinical Pharmacology in Drug Development 9 (4), 466-475, 2020 | 2 | 2020 |
| Viral dynamics modeling of MK-3682 monotherapy in HCV infected patients P Bhagunde, ML Rizk, B Marshall, J Butterton, W Gao Journal of Pharmacokinetics and Pharmacodynamics 42 (1), S104-S105, 2015 | 2 | 2015 |
| Erratum for Rhee et al.,“Pharmacokinetics, Safety, and Tolerability of Single and Multiple Doses of Relebactam, a β-Lactamase Inhibitor, in Combination with Imipenem and … EG Rhee, ML Rizk, N Calder, M Nefliu, SJ Warrington, MS Schwartz, ... Antimicrobial Agents and Chemotherapy 62 (12), 10.1128/aac. 02197-18, 2018 | 1 | 2018 |
| Treatment of hemophilia with fitusiran S Poloskey, S Andersson, PR Bhagunde, Y Cui, S Iqbal, B Mei US Patent App. 18/256,199, 2024 | | 2024 |
| Fitusiran Population Pharmacokinetic and Pharmacodynamic Modeling Utilizing Phase 3 Clinical Trial Data to Confirm Doses Tested in Phase 3 Trials to Support an Antithrombin … K Madrasi, P Bhagunde, S Iqbal, M Puurunen, M Demissie, S Andersson, ... Blood 142, 2614, 2023 | | 2023 |
| A REPEATED TIME TO EVENT (RTTE) MODEL TOCHARACTERIZE BLEED RISK IN PATIENTS WITH SEVEREHEMOPHILIA A TREATED WITH EFANESOCTOCOG ALFA QL Pratik Bhagunde, Anais Glatard, Joakim Nyberg, Suresh Katragadda ... Haemophilia (EAHAD) 29 (S1), 85, 2023 | | 2023 |
